Lana Pine

Of the 333 patients with PsA and 457 patients with axSpA, there were 1.09 serious infections per 100 patient years (95% CI .85 – 1.35).

Patients diagnosed with psoriatic arthritis and obesity were older, more frequently women, had worse pain, physical function, and health-related quality of life, and had higher tender joint and enthesitis counts when compared with nonobese patients.

Of the 130 patients with psoriatic arthritis who participated in a telemedicine assessment, 83% were happy with the consultation.

The biosimilar was deemed comparable and tolerable in terms of safety between groups.

Changes in the serum urate levels, number of gout flares before 1 year of treatment, and tophus were linked to the number of gout flares.

At week 52, patients in the bimekizumab cohort demonstrated sustained clinical responses, which were consistent with results reported at week 16.

All assessed outcomes revealed the treatment effects were significantly better in the external herbal medicine group compared to the control group.

In patients receiving guselkumab, achieving NAPSI 0/1 at week 24 and week 48 was associated with lower baseline NAPSI and week 16 PASI.

Although most clinicians surveyed are unopposed to prescribing adalimumab biosimilars, hesitancies surrounding prescribing practices and an uncertainty of cost savings remains.

Nehad Soloman, MD, believes acknowledging the cultural and social dynamics impacting patients' healthcare decisions and establishing a personal connection with patients can help overcome initial barriers to care.

Patients with fibromyalgia receiving CBT experienced significant improvements in pain interference and larger decreases in pain catastrophizing post-treatment.

Fatigue was positively correlated with the frequency, duration, severity, and chronicity of migraine episodes, as well as excessive daytime sleepiness.

Most patients continued treatment with the adalimumab biosimilar over 2 years, with a treatment retention rate of 73.1%.

JB Boone, MD, explains the progress being made towards more personalized medicine in patients with rheumatoid arthritis, as well as the current challenges.

JB Boone, MD, explains PrismRA, a predictive tool designed to determine whether a patient will likely have an inadequate response to a TNF inhibitor.

A confirmatory efficacy and safety study demonstrated therapeutic equivalence, immunogenicity, pharmacokinetics, and safety of an aflibercept biosimilar.

Significantly greater improvements in back pain and morning stiffness were observed in patients receiving ixekizumab compared with placebo.

Males in the highest serum uric acid tier were significantly more likely to be diagnosed with peripheral artery disease, although a similar trend was not observed in female patients.

The incidences of stroke, ischemic heart disease, or heart failure were slightly higher in patients with gout when compared with controls.

Continued reductions in serum acute phase proteins and collagen degradation proteins observed in patients with psoriatic arthritis receiving guselkumab may be linked to sustained symptom improvements.

Investigators believe a more consistent application of disease activity measures may help to guide treatment decisions and improve quality of care.

Significantly more patients receiving voclosporin had a good renal outcome, defined as achieving adequate response with no renal flare, compared with controls.

A lower proportion of patients in the belimumab treatment group experienced ≥1 kidney flare compared with placebo in the overall population.

Stephen Ziegler, PhD, JD, discusses the challenges cannabis treatment presents as a form of complementary therapy for rheumatic disease.

Stephen Ziegler, PhD, JD, describes the various alternative and complementary treatments available for palliative care and pain management in patients with rheumatic disease.

Stephen Ziegler, PhD, JD, explains pain management and prescribing opioid medications in the wake of Ruan v United States.

Elizabeth Volkmann, MD, MS, explains the current treatment options available for SSc-ILD and how to evaluate and manage this patient population.

Elizabeth Volkmann, MD, MS, discusses systemic sclerosis associated interstitial lung disease and how to evaluate subclinical, clinical, and progressive disease for the best outcome.

Patients with IBD-RA and depression were younger, more likely to be female, and were more frequently White compared with controls.

A higher number of patients receiving guselkumab treatment reported ≥1 improvement as early as week 4, which continued to improve through week 24.